Alumis (ALMS) Competitors $8.82 +0.19 (+2.20%) (As of 12/20/2024 05:15 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrends ALMS vs. ARQT, NRIX, RCUS, KNSA, IMCR, OCUL, MESO, TVTX, NTLA, and PRAXShould you be buying Alumis stock or one of its competitors? The main competitors of Alumis include Arcutis Biotherapeutics (ARQT), Nurix Therapeutics (NRIX), Arcus Biosciences (RCUS), Kiniksa Pharmaceuticals (KNSA), Immunocore (IMCR), Ocular Therapeutix (OCUL), Mesoblast (MESO), Travere Therapeutics (TVTX), Intellia Therapeutics (NTLA), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical products" industry. Alumis vs. Arcutis Biotherapeutics Nurix Therapeutics Arcus Biosciences Kiniksa Pharmaceuticals Immunocore Ocular Therapeutix Mesoblast Travere Therapeutics Intellia Therapeutics Praxis Precision Medicines Alumis (NASDAQ:ALMS) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, community ranking, analyst recommendations and profitability. Does the media prefer ALMS or ARQT? In the previous week, Arcutis Biotherapeutics had 6 more articles in the media than Alumis. MarketBeat recorded 13 mentions for Arcutis Biotherapeutics and 7 mentions for Alumis. Arcutis Biotherapeutics' average media sentiment score of 0.73 beat Alumis' score of 0.55 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alumis 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Arcutis Biotherapeutics 5 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer ALMS or ARQT? Alumis presently has a consensus price target of $26.83, suggesting a potential upside of 204.23%. Arcutis Biotherapeutics has a consensus price target of $15.50, suggesting a potential upside of 3.40%. Given Alumis' stronger consensus rating and higher possible upside, equities research analysts clearly believe Alumis is more favorable than Arcutis Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alumis 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25Arcutis Biotherapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Is ALMS or ARQT more profitable? Alumis has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -140.97%. Alumis' return on equity of 0.00% beat Arcutis Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets AlumisN/A N/A N/A Arcutis Biotherapeutics -140.97%-119.11%-45.95% Does the MarketBeat Community prefer ALMS or ARQT? Arcutis Biotherapeutics received 47 more outperform votes than Alumis when rated by MarketBeat users. However, 100.00% of users gave Alumis an outperform vote while only 64.13% of users gave Arcutis Biotherapeutics an outperform vote. CompanyUnderperformOutperformAlumisOutperform Votes12100.00% Underperform VotesNo VotesArcutis BiotherapeuticsOutperform Votes5964.13% Underperform Votes3335.87% Which has higher valuation & earnings, ALMS or ARQT? Alumis has higher earnings, but lower revenue than Arcutis Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlumisN/AN/AN/AN/AN/AArcutis Biotherapeutics$138.71M12.65-$262.14M-$1.79-8.37 SummaryAlumis beats Arcutis Biotherapeutics on 8 of the 12 factors compared between the two stocks. Ad Brownstone ResearchMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Get Alumis News Delivered to You Automatically Sign up to receive the latest news and ratings for ALMS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALMS vs. The Competition Export to ExcelMetricAlumisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$416.50M$6.57B$5.13B$9.07BDividend YieldN/A2.99%5.08%4.23%P/E RatioN/A10.4289.5817.17Price / SalesN/A195.801,116.12116.95Price / CashN/A57.1642.8237.86Price / BookN/A5.094.774.78Net IncomeN/A$151.83M$120.15M$225.60M7 Day Performance5.13%-2.13%-1.92%-1.23%1 Month Performance-6.57%-3.10%11.47%3.36%1 Year PerformanceN/A11.54%30.54%16.60% Alumis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALMSAlumisN/A$8.82+2.2%$26.83+204.2%N/A$416.50MN/A0.00N/AAnalyst ForecastLockup ExpirationNews CoveragePositive NewsHigh Trading VolumeARQTArcutis Biotherapeutics0.8599 of 5 stars$13.31+4.9%$15.50+16.5%+478.8%$1.56B$138.71M-7.58150Options VolumePositive NewsNRIXNurix Therapeutics2.5066 of 5 stars$21.13+4.2%$30.35+43.6%+101.7%$1.50B$56.42M-6.97300News CoverageRCUSArcus Biosciences2.6476 of 5 stars$16.26+1.1%$34.00+109.1%-9.3%$1.49B$117M-5.11500News CoverageKNSAKiniksa Pharmaceuticals2.5299 of 5 stars$20.50+1.5%$36.60+78.5%+15.4%$1.48B$384.10M-147.36220Positive NewsIMCRImmunocore2.4974 of 5 stars$29.12+0.7%$65.64+125.4%-51.4%$1.46B$296.31M-30.43497Short Interest ↓OCULOcular Therapeutix3.6461 of 5 stars$9.04+4.0%$16.71+84.9%+116.8%$1.42B$58.44M0.00267Positive NewsMESOMesoblast1.0377 of 5 stars$12.16+3.4%$11.50-5.4%+590.1%$1.39B$5.90M0.0080Analyst ForecastOptions VolumeNews CoveragePositive NewsTVTXTravere Therapeutics2.7678 of 5 stars$17.73+2.4%$22.62+27.6%+106.0%$1.38B$145.24M-3.81460Positive NewsNTLAIntellia Therapeutics4.132 of 5 stars$13.50+4.7%$54.94+306.9%-58.9%$1.37B$36.28M-2.37600PRAXPraxis Precision Medicines2.4033 of 5 stars$72.35+3.1%$146.33+102.3%+323.0%$1.35B$2.45M-7.06110Gap DownHigh Trading Volume Related Companies and Tools Related Companies ARQT Alternatives NRIX Alternatives RCUS Alternatives KNSA Alternatives IMCR Alternatives OCUL Alternatives MESO Alternatives TVTX Alternatives NTLA Alternatives PRAX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALMS) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alumis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alumis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
